Digest Network Come funziona
Network
/
Società
Le
Non verificato

Leyden Laboratories B.V.

Di cosa scriviamo

BiotecnologiaFarmaceuticaHIV, AIDS e malattie autoimmuniIndustriaSalute

5 comunicati stampa

Guarda tutti i comunicati
02/10/2025
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Medicina - Varie
Industria
Leyden Labs Secures €30 million from European Innovation Council Fund and Invest-NL to Advance Nasal Spray Against Respiratory Viruses
Fonte
Leyden Laboratories B.V.
Emittente
Business Wire
1.00
0
03/06/2025
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Mercato del lavoro
Industria
Leyden Labs Lands €20 Million EIB Investment Facilitated by HERA to Advance Pandemic Preparedness Activities
Fonte
Leyden Laboratories B.V.
Emittente
Business Wire
1.00
0
08/04/2025
Industria
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Leyden Labs Publishes New Data Confirming Potential of Intranasal Antibody Approach
Fonte
Leyden Laboratories B.V.
Emittente
Business Wire
1.00
0
09/01/2025
Fiere
Biotecnologia
Sanità
Salute
Leyden Labs Raises $70M to Advance its Intranasal Antibody Programs to Protect against Influenza and other Viruses
Fonte
Leyden Laboratories B.V.
Emittente
Business Wire
1.00
0
12/09/2024
Mercato del lavoro
Salute
HIV, AIDS e malattie autoimmuni
Scienza
Farmaceutica
Biotecnologia
Leyden Labs Appoints Jintanat Ananworanich, M.D., Ph.D., as Chief Medical Officer
Fonte
Leyden Laboratories B.V.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0